Dechra is pleased to announce the acquisition of Zimeta® (dipyrone injection) from Elanco™ Animal Health. Zimeta is the first and only FDA-approved drug for the control of pyrexia in horses. Dechra has been distributing Zimeta in the US since January 2021 and has now acquired the registrations. Veterinary customers will not experience any change in how they order the product.
Mike Eldred, president of Dechra North America, stated, “This acquisition provides veterinarians a novel fever-reducing medication as Dechra continues an aggressive equine portfolio expansion.”
About Dechra
Dechra Veterinary Products’ equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet APC™ (Autologous Platelet Concentrate) system, Rompun® (xylazine injection), Butorphanol Tartrate Injection, Isoflurane, USP Inhalant Anesthetic, and SucroMate® Equine (deslorelin acetate) further expand Dechra’s equine offerings.
![[Aggregator] Downloaded image for imported item #18386](https://s3.amazonaws.com/wp-s3-equimanagement.com/wp-content/uploads/2025/09/30141347/EDCC-Unbranded-12-scaled-1-768x512.jpeg)
